MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity

Neuron

Volumn 83, Issue 2, 2014, Pages 344-360

  Issler, Orna ^a,b   Haramati, Sharon ^a   Paul, Evan D ^c   Maeno, Hiroshi ^d   Navon, Inbal ^a   Zwang, Rayya ^a   Gil, Shosh ^a   Mayberg, Helen S ^e   Dunlop, Boadie W ^e   Menke, Andreas ^b   Awatramani, Rajeshwar ^f   Binder, Elisabeth B ^b,e   Deneris, Evan S ^d   Lowry, Christopher A ^c   Chen, Alon ^a,b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c UNIVERSITY OF COLORADO   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; IMIPRAMINE; MICRORNA; MICRORNA 135; MICRORNA 135A; REBOXETINE; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BRAIN LEVEL; CELL ACTIVITY; CHRONIC STRESS; CONTROLLED STUDY; COPING BEHAVIOR; DEPRESSION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN TISSUE; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTONIN METABOLISM; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; DEPRESSION; MICE; MICE, TRANSGENIC; MICRORNAS; RECEPTOR, SEROTONIN, 5-HT1A; RESILIENCE, PSYCHOLOGICAL; SEROTONERGIC NEURONS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SOCIAL BEHAVIOR; STRESS, PSYCHOLOGICAL;

EID: 84904368019     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2014.05.042     Document Type: Article

References (79)

1. Albert P.R., François B.L. Modifying 5-HT1A receptor gene expression as a new target for antidepressant therapy. Front Neurosci 2010, 4:35.
2. Anderegg A., Lin H.P., Chen J.A., Caronia-Brown G., Cherepanova N., Yun B., Joksimovic M., Rock J., Harfe B.D., Johnson R., Awatramani R. An Lmx1b-miR135a2 regulatory circuit modulates Wnt1/Wnt signaling and determines the size of the midbrain dopaminergic progenitor pool. PLoS Genet. 2013, 9:e1003973.
3. Ansorge M.S., Hen R., Gingrich J.A. Neurodevelopmental origins of depressive disorders. Curr. Opin. Pharmacol. 2007, 7:8-17.
4. Baldwin D.S., Anderson I.M., Nutt D.J., Bandelow B., Bond A., Davidson J.R., den Boer J.A., Fineberg N.A., Knapp M., Scott J., Wittchen H.U. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J.Psychopharmacol. (Oxford) 2005, 19:567-596. British Association for Psychopharmacology.
5. Baroukh N.N., Van Obberghen E. Function of microRNA-375 and microRNA-124a in pancreas and brain. FEBS J. 2009, 276:6509-6521.
6. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
7. Baudry A., Mouillet-Richard S., Schneider B., Launay J.M., Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 2010, 329:1537-1541.
8. Belzeaux R., Bergon A., Jeanjean V., Loriod B., Formisano-Tréziny C., Verrier L., Loundou A., Baumstarck-Barrau K., Boyer L., Gall V., et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transcult. Psychiatry 2012, 2:e185.
9. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 2006, 7:137-151.
10. Berton O., McClung C.A., Dileone R.J., Krishnan V., Renthal W., Russo S.J., Graham D., Tsankova N.M., Bolanos C.A., Rios M., et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006, 311:864-868.
11. Bocchio-Chiavetto L., Maffioletti E., Bettinsoli P., Giovannini C., Bignotti S., Tardito D., Corrada D., Milanesi L., Gennarelli M. Blood microRNA changes in depressed patients during antidepressant treatment. Eur. Neuropsychopharmacol. 2013, 23:602-611.
12. Bortolozzi A., Castañé A., Semakova J., Santana N., Alvarado G., Cortés R., Ferrés-Coy A., Fernández G., Carmona M.C., Toth M., et al. Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects. Mol. Psychiatry 2012, 17:612-623.
13. Creson T.K., Austin D.R., Shaltiel G., McCammon J., Wess J., Manji H.K., Chen G. Lithium treatment attenuates muscarinic M(1) receptor dysfunction. Bipolar Disord. 2011, 13:238-249.
14. Curtis D., Kalsi G., Brynjolfsson J., McInnis M., O'Neill J., Smyth C., Moloney E., Murphy P., McQuillin A., Petursson H., Gurling H. Genome scan of pedigrees multiply affected with bipolar disorder provides further support for the presence of a susceptibility locus on chromosome 12q23-q24, and suggests the presence of additional loci on 1p and 1q. Psychiatr. Genet. 2003, 13:77-84.
15. Dawson E., Parfitt E., Roberts Q., Daniels J., Lim L., Sham P., Nöthen M., Propping P., Lanczik M., Maier W., et al. Linkage studies of bipolar disorder in the region of the Darier's disease gene on chromosome 12q23-24.1. Am. J. Med. Genet. 1995, 60:94-102.
16. Deakin J.F., Graeff F.G. 5-HT and mechanisms of defence. Author's response. J.Psychopharmacol. (Oxford) 1991, 5:339-341.
17. Detera-Wadleigh S.D., Badner J.A., Berrettini W.H., Yoshikawa T., Goldin L.R., Turner G., Rollins D.Y., Moses T., Sanders A.R., Karkera J.D., et al. A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2. Proc. Natl. Acad. Sci. USA 1999, 96:5604-5609.
18. Dunlop B.W., Kelley M.E., Mletzko T.C., Velasquez C.M., Craighead W.E., Mayberg H.S. Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. J.Psychiatr. Res. 2012, 46:375-381.
19. Ekholm J.M., Kieseppä T., Hiekkalinna T., Partonen T., Paunio T., Perola M., Ekelund J., Lönnqvist J., Pekkarinen-Ijäs P., Peltonen L. Evidence of susceptibility loci on 4q32 and 16p12 for bipolar disorder. Hum. Mol. Genet. 2003, 12:1907-1915.
20. Elliott E., Ezra-Nevo G., Regev L., Neufeld-Cohen A., Chen A. Resilience to social stress coincides with functional DNA methylation of the Crf gene in adult mice. Nat. Neurosci. 2010, 13:1351-1353.
21. Evans A.K., Reinders N., Ashford K.A., Christie I.N., Wakerley J.B., Lowry C.A. Evidence for serotonin synthesis-dependent regulation of invitro neuronal firing rates in the midbrain raphe complex. Eur. J. Pharmacol. 2008, 590:136-149.
22. Fakra E., Hyde L.W., Gorka A., Fisher P.M., Muñoz K.E., Kimak M., Halder I., Ferrell R.E., Manuck S.B., Hariri A.R. Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety. Arch. Gen. Psychiatry 2009, 66:33-40.
23. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19:92-105.
24. Gardner K.L., Thrivikraman K.V., Lightman S.L., Plotsky P.M., Lowry C.A. Early life experience alters behavior during social defeat: focus on serotonergic systems. Neuroscience 2005, 136:181-191.
25. Graeff F.G., Guimarães F.S., De Andrade T.G., Deakin J.F. Role of 5-HT in stress, anxiety, and depression. Pharmacol. Biochem. Behav. 1996, 54:129-141.
26. Green E.K., Elvidge G.P., Owen M.J., Craddock N. Mutational analysis of two positional candidate susceptibility genes for bipolar disorder on chromosome 12q23-q24: phenylalanine hydroxylase and human LIM-homeobox LHX5. Psychiatr. Genet. 2003, 13:97-101.
27. Hale M.W., Lowry C.A. Functional topography of midbrain and pontine serotonergic systems: implications for synaptic regulation of serotonergic circuits. Psychopharmacology (Berl.) 2011, 213:243-264.
28. Haramati S., Navon I., Issler O., Ezra-Nevo G., Gil S., Zwang R., Hornstein E., Chen A. MicroRNA as repressors of stress-induced anxiety: the case of amygdalar miR-34. J.Neurosci. 2011, 31:14191-14203.
29. Holmes A., Murphy D.L., Crawley J.N. Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. Biol. Psychiatry 2003, 54:953-959.
30. Homberg J.R., Lesch K.P. Looking on the bright side of serotonin transporter gene variation. Biol. Psychiatry 2011, 69:513-519.
31. Hornung J.P. The human raphe nuclei and the serotonergic system. J.Chem. Neuroanat. 2003, 26:331-343.
32. Jensen K.P., Covault J., Conner T.S., Tennen H., Kranzler H.R., Furneaux H.M. A common polymorphism in serotonin receptor 1B mRNA moderates regulation by miR-96 and associates with aggressive human behaviors. Mol. Psychiatry 2009, 14:381-389.
33. Kocerha J., Faghihi M.A., Lopez-Toledano M.A., Huang J., Ramsey A.J., Caron M.G., Sales N., Willoughby D., Elmen J., Hansen H.F., et al. MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc. Natl. Acad. Sci. USA 2009, 106:3507-3512.
34. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
35. Krishnan V., Han M.H., Graham D.L., Berton O., Renthal W., Russo S.J., Laplant Q., Graham A., Lutter M., Lagace D.C., et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 2007, 131:391-404.
36. Kuperman Y., Issler O., Vaughan J., Bilezikjian L., Vale W., Chen A. Expression and regulation of corticotropin-releasing factor receptor type 2β in developing and mature mouse skeletal muscle. Mol. Endocrinol. 2011, 25:157-169.
37. Kye M.J., Neveu P., Lee Y.S., Zhou M., Steen J.A., Sahin M., Kosik K.S., Silva A.J. NMDA mediated contextual conditioning changes miRNA expression. PLoS ONE 2011, 6:e24682.
38. Lebow M., Neufeld-Cohen A., Kuperman Y., Tsoory M., Gil S., Chen A. Susceptibility to PTSD-like behavior is mediated by corticotropin-releasing factor receptor type 2 levels in the bed nucleus of the stria terminalis. J.Neurosci. 2012, 32:6906-6916.
39. Li Y.J., Xu M., Gao Z.H., Wang Y.Q., Yue Z., Zhang Y.X., Li X.X., Zhang C., Xie S.Y., Wang P.Y. Alterations of serum levels of BDNF-related miRNAs in patients with depression. PLoS ONE 2013, 8:e63648.
40. Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
41. Lowry C.A. Functional subsets of serotonergic neurones: implications for control of the hypothalamic-pituitary-adrenal axis. J.Neuroendocrinol. 2002, 14:911-923.
42. Manji H.K., Drevets W.C., Charney D.S. The cellular neurobiology of depression. Nat. Med. 2001, 7:541-547.
43. Masand P.S. Tolerability and adherence issues in antidepressant therapy. Clin. Ther. 2003, 25:2289-2304.
44. McMahon F.J., Akula N., Schulze T.G., Muglia P., Tozzi F., Detera-Wadleigh S.D., Steele C.J., Breuer R., Strohmaier J., Wendland J.R., et al. Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat. Genet. 2010, 42:128-131. Bipolar Disorder Genome Study (BiGS) Consortium.
45. Meltzer H.Y., Maes M. Effects of ipsapirone on plasma cortisol and body temperature in major depression. Biol. Psychiatry 1995, 38:450-457.
46. Menke A., Arloth J., Pütz B., Weber P., Klengel T., Mehta D., Gonik M., Rex-Haffner M., Rubel J., Uhr M., et al. Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology 2012, 37:1455-1464.
47. Merali Z., Kent P., Du L., Hrdina P., Palkovits M., Faludi G., Poulter M.O., Bédard T., Anisman H. Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations instress-relevant brain regions of suicides and control subjects. Biol. Psychiatry 2006, 59:594-602.
48. Moncrieff J., Kirsch I. Efficacy of antidepressants in adults. BMJ 2005, 331:155-157.
49. Moskvina V., Craddock N., Holmans P., Nikolov I., Pahwa J.S., Green E., Owen M.J., O'Donovan M.C. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol. Psychiatry 2009, 14:252-260. Wellcome Trust Case Control Consortium.
50. Muiños-Gimeno M., Espinosa-Parrilla Y., Guidi M., Kagerbauer B., Sipilä T., Maron E., Pettai K., Kananen L., Navinés R., Martín-Santos R., et al. Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 are associated with panic disorder and regulate several anxiety candidate genes and related pathways. Biol. Psychiatry 2011, 69:526-533.
51. Müller M.B., Wurst W. Getting closer to affective disorders: the role of CRH receptor systems. Trends Mol. Med. 2004, 10:409-415.
52. Murphy D.L., Fox M.A., Timpano K.R., Moya P.R., Ren-Patterson R., Andrews A.M., Holmes A., Lesch K.P., Wendland J.R. How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology 2008, 55:932-960.
53. Neufeld-Cohen A., Tsoory M.M., Evans A.K., Getselter D., Gil S., Lowry C.A., Vale W.W., Chen A. A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery. Proc. Natl. Acad. Sci. USA 2010, 107:19020-19025.
54. O'Connor R.M., Dinan T.G., Cryan J.F. Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression. Mol. Psychiatry 2012, 17:359-376.
55. Ohta Y., Kosaka Y., Kishimoto N., Wang J., Smith S.B., Honig G., Kim H., Gasa R.M., Neubauer N., Liou A., et al. Convergence of the insulin and serotonin programs in the pancreatic β-cell. Diabetes 2011, 60:3208-3216.
56. Paxinos G., Franklin K.N.J. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego.
57. Piva F., Giulietti M., Nardi B., Bellantuono C., Principato G. An improved insilico selection of phenotype affecting polymorphisms in SLC6A4, HTR1A and HTR2A genes. Hum. Psychopharmacol. 2010, 25:153-161.
58. Regev L., Neufeld-Cohen A., Tsoory M., Kuperman Y., Getselter D., Gil S., Chen A. Prolonged and site-specific over-expression of corticotropin-releasing factor reveals differential roles for extended amygdala nuclei in emotional regulation. Mol. Psychiatry 2011, 16:714-728.
59. Reid G., Kirschner M.B., van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit. Rev. Oncol. Hematol. 2011, 80:193-208.
60. Richardson-Jones J.W., Craige C.P., Guiard B.P., Stephen A., Metzger K.L., Kung H.F., Gardier A.M., Dranovsky A., David D.J., Beck S.G., et al. 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 2010, 65:40-52.
61. Rinaldi A., Vincenti S., De Vito F., Bozzoni I., Oliverio A., Presutti C., Fragapane P., Mele A. Stress induces region specific alterations in microRNAs expression in mice. Behav. Brain Res. 2010, 208:265-269.
62. Saus E., Soria V., Escaramís G., Vivarelli F., Crespo J.M., Kagerbauer B., Menchón J.M., Urretavizcaya M., Gratacòs M., Estivill X. Genetic variants and abnormal processing of pre-miR-182, a circadian clock modulator, in major depression patients with late insomnia. Hum. Mol. Genet. 2010, 19:4017-4025.
63. Savitz J., Lucki I., Drevets W.C. 5-HT(1A) receptor function in major depressive disorder. Prog. Neurobiol. 2009, 88:17-31.
64. Schloss P., Henn F.A. New insights into the mechanisms of antidepressant therapy. Pharmacol. Ther. 2004, 102:47-60.
65. Schloss P., Williams D.C. The serotonin transporter: a primary target for antidepressant drugs. J.Psychopharmacol. (Oxford) 1998, 12:115-121.
66. Scott M.M., Wylie C.J., Lerch J.K., Murphy R., Lobur K., Herlitze S., Jiang W., Conlon R.A., Strowbridge B.W., Deneris E.S. A genetic approach to access serotonin neurons for invivo and invitro studies. Proc. Natl. Acad. Sci. USA 2005, 102:16472-16477.
67. Scott L.J., Muglia P., Kong X.Q., Guan W., Flickinger M., Upmanyu R., Tozzi F., Li J.Z., Burmeister M., Absher D., et al. Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc. Natl. Acad. Sci. USA 2009, 106:7501-7506.
68. Smalheiser N.R., Lugli G., Rizavi H.S., Zhang H., Torvik V.I., Pandey G.N., Davis J.M., Dwivedi Y. MicroRNA expression in rat brain exposed to repeated inescapable shock: differential alterations in learned helplessness vs. non-learned helplessness. Int. J. Neuropsychopharmacol. 2011, 14:1315-1325.
69. Smalheiser N.R., Lugli G., Rizavi H.S., Torvik V.I., Turecki G., Dwivedi Y. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS ONE 2012, 7:e33201.
70. Sztainberg Y., Kuperman Y., Justice N., Chen A. An anxiolytic role for CRF receptor type 1 in the globus pallidus. J.Neurosci. 2011, 31:17416-17424.
71. Thakker D.R., Natt F., Hüsken D., van der Putten H., Maier R., Hoyer D., Cryan J.F. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol. Psychiatry 2005, 10:782-789.714.
72. Tiscornia G., Singer O., Verma I.M. Production and purification of lentiviral vectors. Nat. Protoc. 2006, 1:241-245.
73. Turecki G., Smith M., Mari J.J. Type I bipolar disorder associated with a fragile site on chromosome 1. Am. J. Med. Genet. 1995, 60:179-182.
74. Uchida S., Nishida A., Hara K., Kamemoto T., Suetsugi M., Fujimoto M., Watanuki T., Wakabayashi Y., Otsuki K., McEwen B.S., Watanabe Y. Characterization of the vulnerability to repeated stress in Fischer 344 rats: possible involvement of microRNA-mediated down-regulation of the glucocorticoid receptor. Eur. J. Neurosci. 2008, 27:2250-2261.
75. Ustün T.B., Ayuso-Mateos J.L., Chatterji S., Mathers C., Murray C.J. Global burden of depressive disorders in the year 2000. Br. J. Psychiatry 2004, 184:386-392.
76. Wang P.S., Lane M., Olfson M., Pincus H.A., Wells K.B., Kessler R.C. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005, 62:629-640.
77. Wylie C.J., Hendricks T.J., Zhang B., Wang L., Lu P., Leahy P., Fox S., Maeno H., Deneris E.S. Distinct transcriptomes define rostral and caudal serotonin neurons. J.Neurosci. 2010, 30:670-684.
78. Xu Y., Liu H., Li F., Sun N., Ren Y., Liu Z., Cao X., Wang Y., Liu P., Zhang K. A polymorphism in the microRNA-30e precursor associated with major depressive disorder risk and P300 waveform. J.Affect. Disord. 2010, 127:332-336.
79. Zhou R., Yuan P., Wang Y., Hunsberger J.G., Elkahloun A., Wei Y., Damschroder-Williams P., Du J., Chen G., Manji H.K. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 2009, 34:1395-1405.